title: Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome.
abstract: OBJECTIVE
  To evaluate whether three daily doses of GnRH agonist (Inj. Lupride 1 mg SC) administered 6 days after oocyte retrieval increases ongoing pregnancy rates following embryo transfer (ET) in cycles stimulated with the long GnRH agonist protocol.
  
  
  METHODS
  Prospective randomized controlled study in a tertiary care center.
  
  
  METHODS
  Four hundred and twenty six women undergoing ET following controlled ovarian stimulation with a long GnRH agonist protocol were included. In addition to routine luteal-phase support (LPS) with progesterone, women were randomized to receive three 1 mg doses of Lupride 6 days after oocyte retrieval. Computer-generated randomization was done on the day of ET. Ongoing pregnancy rate beyond 20(th) week of gestation was the primary outcome measure. The trial was powered to detect a 13% absolute increase from an assumed 27% ongoing pregnancy rate in the control group, with an alpha error level of 0.05 and a beta error level of 0.2.
  
  
  RESULTS
  There were 59 (27.69%) ongoing pregnancies in the GnRHa group, and 56 (26.29%) in the control group (P = 0.827). Implantation, clinical pregnancy and multiple pregnancy rates were likewise similar in the GnRHa and placebo groups.
  
  
  CONCLUSIONS
  Three 1 mg doses of Lupride administration 6 days after oocyte retrieval in the long protocol cycles does not result in an increase in ongoing pregnancy rates.
authors.affiliation: Department of Obstetrics and Gynecology, Fellow in Reproductive Medicine, Sir Ganga Ram Hospital, New Delhi, India.
authors.forename: Dattaprasad B
authors.initials: DB
authors.lastname: Inamdar
authors.forename: Abha
authors.initials: A
authors.lastname: Majumdar
keywords: GnRH agonist; implantation rate; luteal-phase adjuvant; ongoing pregnancy